Viking Therapeutics Completes Phase 3 VANQUISH-2 Enrollment for VK2735
Viking enrolled ~1,000 adults in the 78-week trial of VK2735, a GLP-1/GIP dual agonist. Phase 2 showed up to 14.7% body weight reduction in just 13 weeks.
#vk2735
1 story
1 story
Viking enrolled ~1,000 adults in the 78-week trial of VK2735, a GLP-1/GIP dual agonist. Phase 2 showed up to 14.7% body weight reduction in just 13 weeks.